The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...

Researchers at the Thoracic Surgery research group, the Department of Molecular Medicine and Surgery, have performed a study of patients who underwent bioprosthetic aortic valve replacement in ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

Edwards Lifesciences (NYSE: EW) today announced eight-year data highlighting positive long-term outcomes with its proprietary ...

CALC is the principal failure mode of BHV fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. Covalent binding of APD to residual glutaraldehyde in pericardial ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary ...

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

Nat Clin Pract Cardiovasc Med. 2008;5(12):764-765. We believe that strategies to avoid or reduce the severity of PPM should be individualized and take into account multiple variables, such as ...

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement ... to significantly less bioprosthetic valve dysfunction, five ...